Selected article for: "clinical manifestation and SARS infection"
Author: Mastaglio, Sara; Ruggeri, Annalisa; Risitano, Antonio M.; Angelillo, Piera; Yancopoulou, Despina; Mastellos, Dimitrios C.; Huber-Lang, Markus; Piemontese, Simona; Assanelli, Andrea; Garlanda, Cecilia; Lambris, John D.; Ciceri, Fabio
Title: The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
  • Cord-id: m0omw4xf
  • Document date: 2020_4_29
    • ID: m0omw4xf
    Snippet: Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung in
    Document: Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.

    Search related documents:
    Co phrase search for related documents
    • absolute alc lymphocyte count and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • absolute alc lymphocyte count and lung function: 1, 2
    • absolute alc lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
    • absolute anc neutrophil count and acute ards respiratory distress syndrome: 1
    • absolute anc neutrophil count and acute respiratory: 1, 2, 3, 4, 5, 6
    • absolute anc neutrophil count and acute respiratory distress syndrome: 1, 2
    • absolute anc neutrophil count and acute respiratory syndrome: 1, 2, 3, 4
    • absolute anc neutrophil count and administration start: 1
    • absolute anc neutrophil count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and loading dose: 1
    • acute ards respiratory distress syndrome and lung auscultation: 1, 2, 3
    • acute ards respiratory distress syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and lung direct: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
    • acute ards respiratory distress syndrome and lung functional: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute ards respiratory distress syndrome and lymphocytopenia leukocytosis: 1
    • acute respiratory and additional lab testing: 1
    • acute respiratory and administration start: 1